Studieoverzicht
Study name: Tropion-Lung 07
| Histology | NSCLC |
|---|---|
| Tumor stage | Stage IV |
| Host / recruiting sites | LUMC |
| Enrollment | Recruiting |
| Therapy line | First line (1L) |
| Design |
Gerandomiseerde fase 3 studie |
| Intervention | Dato-DXd (Datopotamab Deruxtecan) icm Pembrolizumab vs Dato-DXd icm Pembrolizumab en platinum bevattende chemotherapie vs Pembrolizumab en platinum bevattende chemotherapie |
| Key outcome parameters | PFS, OS |
| Key inclusion criteria | Stadium IIIB-IV NSCLC zonder driver mutatie PD-L1 <50%, geen eerdere systeemtherapie |
| Key exclusion criteria | Symptomatische CNS metastasen Co-morbiditeit oa LVEF <50%, ILD, equivalent >10mg prednison |
| Contact information | Log in voor de contactinformatie |